Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

被引：8
|
作者：
Fushimi, Chihiro [1 ]
Baba, Daisuke [1 ]
Masubuchi, Tatsuo [1 ]
Yamazaki, Morio [1 ]
Kitani, Yosuke [1 ]
Kitajima, Tatsuya [1 ]
Tanaka, Junpei [1 ]
Hanyu, Kenji [1 ]
Tanaka, Naruhisa [1 ]
Miura, Kouki [1 ]
Tada, Yuichiro [1 ]
机构：
[1] Int Univ Hlth & Welf, Dept Head & Neck Oncol & Surg, Mita Hosp, Tokyo, Japan
来源：
IN VIVO | 2020年 / 34卷 / 05期
关键词：
Head and neck squamous cell carcinoma; paclitaxel; cetuximab; recurrent; metastasis; PLATINUM-BASED CHEMOTHERAPY; RECURRENT/METASTATIC HEAD; PLUS CETUXIMAB; COMBINATION; FAILURE; CANCER;
D O I：
10.21873/invivo.12084
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX). Patients and Methods: The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events. Results: The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not. Conclusion: Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
引用
收藏
页码：2653 / 2657
页数：5
相关论文
共 50 条
  • [1] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [2] Predictors of Outcome With Cetuximab and Paclitaxel for Head and Neck Squamous Cell Carcinoma
    Ferreira, Bruna Pellini
    Redman, Mary
    Baker, Kelsey K.
    Martins, Renato
    Eaton, Keith D.
    Chow, Laura Quan Man
    Baik, Christina S.
    Goulart, Bernardo
    Lee, Sylvia Mina
    Santana-Davila, Rafael
    Rodriguez, Cristina P.
    LARYNGOSCOPE, 2017, 127 (07) : 1583 - 1588
  • [3] Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
    Chevalier, Thomas
    Daste, Amaury
    Saada-Bouzid, Esmaa
    Loundou, Anderson
    Peyraud, Florent
    Lambert, Tiphaine
    Le Tourneau, Christophe
    Peyrade, Frederic
    Dupuis, Charlotte
    Alfonsi, Marc
    Fayette, Jerome
    Reure, Juliette
    Huguet, Florence
    Fakhry, Nicolas
    Toullec, Clemence
    Salas, Sebastien
    CANCER MEDICINE, 2021, 10 (12): : 3952 - 3963
  • [4] Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    Pajares Bernad, I.
    Martinez Trufero, J.
    Calera Urquizu, L.
    Pazo Cid, R. A.
    Cebollero de Miguel, A.
    Agustin, M. J.
    Lanzuela, M.
    Anton, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06) : 769 - 776
  • [5] Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Kodama, Hiroyuki
    Kadowaki, Shigenori
    Ishizuka, Yasunobu
    Wakabayashi, Munehiro
    Sakakida, Tomoki
    Honda, Kazunori
    Masuishi, Toshiki
    Narita, Yukiya
    Taniguchi, Hiroya
    Ando, Masashi
    Kishikawa, Toshihiro
    Terada, Hoshino
    Beppu, Shintaro
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Hanai, Nobuhiro
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 480 - 488
  • [6] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [7] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Risa Motai
    Michi Sawabe
    Shigenori Kadowaki
    Eiichi Sasaki
    Daisuke Nishikawa
    Hidenori Suzuki
    Shintaro Beppu
    Hoshino Terada
    Nobuhiro Hanai
    International Journal of Clinical Oncology, 2021, 26 : 1188 - 1195
  • [8] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Motai, Risa
    Sawabe, Michi
    Kadowaki, Shigenori
    Sasaki, Eiichi
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Beppu, Shintaro
    Terada, Hoshino
    Hanai, Nobuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1188 - 1195
  • [9] Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma
    Okada, Takuro
    Okamoto, Isaku
    Sato, Hiroki
    Ito, Tatsuya
    Miyake, Keitaro
    Tsukahara, Kiyoaki
    IN VIVO, 2021, 35 (02): : 1253 - 1259
  • [10] Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
    Naruse, Tomofumi
    Yanamoto, Souichi
    Otsuru, Mitsunobu
    Yamakawa, Nobuhiro
    Kirita, Tadaaki
    Shintani, Yukari
    Matsumura, Tatsushi
    Okura, Masaya
    Sasaki, Masashi
    Ota, Yoshihide
    Yamada, Shin-ichi
    Kurita, Hiroshi
    Umeda, Masahiro
    ANTICANCER RESEARCH, 2021, 41 (11) : 5785 - 5791
12345